Partridge C J, Beech D J, Sivaprasadarao A
School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
J Biol Chem. 2001 Sep 21;276(38):35947-52. doi: 10.1074/jbc.M104762200. Epub 2001 Jul 16.
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a genetic disorder characterized by excess secretion of insulin and hypoglycemia. In most patients, the disease is caused by mutations in sulfonylurea receptor-1 (SUR1), which, in association with Kir6.2, constitutes the functional ATP-sensitive potassium (K(ATP)) channel of the pancreatic beta-cell. Previous studies reported that coexpression of the PHHI mutant R1394H-SUR1 with Kir6.2 in COS cells produces no functional channels. To investigate if the loss of function could be due to impaired trafficking of mutant channels to the cell membrane, we have cotransfected wild-type and mutant SUR1 subunits with Kir6.2 into HEK293 cells and examined their cellular localization by immunofluorescent staining. Our results show that unlike the wild-type subunits, which showed fluorescence at the cell surface, the mutant subunits displayed fluorescence in punctate structures. Co-immunostaining with antibodies against organelle-specific marker proteins identified these structures as the trans-Golgi network. Limited localization in clathrin-positive, but transferrin receptor-negative vesicles was also observed. The post-endoplasmic reticulum localization suggests that the mutation does not impair the folding and assembly of the channels so as to cause its retention by the endoplasmic reticulum. Diazoxide, a K(ATP) channel opener drug that is used in the treatment of PHHI, restored the surface expression in a manner that could be prevented by the channel blocker glibenclamide. When expressed in Xenopus oocytes, R1394H-SUR1 formed functional channels with Kir6.2, indicating that the primary consequence of the mutation is impairment of trafficking rather than function. Thus, our data uncover a novel mechanism underlying the therapeutic action of diazoxide in the treatment of PHHI, i.e. its ability to recruit channels to the membrane. Furthermore, this is the first report to describe a trafficking disorder effecting retention of mutant proteins in the trans-Golgi network.
婴儿持续性高胰岛素血症性低血糖症(PHHI)是一种遗传性疾病,其特征是胰岛素分泌过多和低血糖。在大多数患者中,该疾病由磺脲类受体1(SUR1)突变引起,SUR1与Kir6.2共同构成胰腺β细胞的功能性ATP敏感性钾(K(ATP))通道。先前的研究报道,PHHI突变体R1394H-SUR1与Kir6.2在COS细胞中共表达不会产生功能性通道。为了研究功能丧失是否可能是由于突变通道向细胞膜的运输受损,我们将野生型和突变型SUR1亚基与Kir6.2共转染到HEK293细胞中,并通过免疫荧光染色检查它们的细胞定位。我们的结果表明,与在细胞表面显示荧光的野生型亚基不同,突变亚基在点状结构中显示荧光。用针对细胞器特异性标记蛋白的抗体进行共免疫染色将这些结构鉴定为反式高尔基体网络。还观察到在网格蛋白阳性但转铁蛋白受体阴性囊泡中的定位有限。内质网后定位表明该突变不会损害通道的折叠和组装,从而导致其被内质网滞留。二氮嗪是一种用于治疗PHHI的K(ATP)通道开放剂药物,它以一种可被通道阻滞剂格列本脲阻止的方式恢复了表面表达。当在非洲爪蟾卵母细胞中表达时,R1394H-SUR1与Kir6.2形成功能性通道,表明该突变的主要后果是运输受损而非功能受损。因此,我们的数据揭示了二氮嗪治疗PHHI的治疗作用的一种新机制,即其将通道募集到膜上的能力。此外,这是第一份描述影响突变蛋白在反式高尔基体网络中滞留的运输障碍的报告。